Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00531024

Systemic Avastin Therapy in Age-Related Macular Degeneration (BEAT-AMD)

Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration

Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Interventions Bevacizumab Sodium Chloride

Updated 6 times since 2017 Last updated: Apr 20, 2009 Started: Aug 31, 2005 Primary completion: Jan 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Macular Degeneration and is currently completed. The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Data source: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria